Pancreatic cancer: How can we progress?
- 31 December 1993
- journal article
- editorial
- Published by Elsevier in European Journal Of Cancer
- Vol. 29 (2) , 171-172
- https://doi.org/10.1016/0959-8049(93)90167-e
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Activity of cisplatin in adenocarcinoma of the pancreasEuropean Journal Of Cancer, 1993
- A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinomaCancer, 1991
- Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A mid-atlantic oncology program studyCancer, 1991
- Biology of pancreatic cancer.Gut, 1991
- A phase III trial on the therapy of advanced pancreatic carcinoma evaluations of the mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatinCancer, 1990
- Evaluation of Receptors for Somatostatin in Various Tumors Using Different Analogs*Journal of Clinical Endocrinology & Metabolism, 1990
- Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genesPublished by Elsevier ,1988
- A Comparison of Three Chemotherapeutic Regimens in the Treatment of Advanced Pancreatic and Gastric CarcinomaJAMA, 1985
- Cis-Diaminodichloroplatinum (II) Chemotherapy for Advanced Adenocarcinoma of the Upper Gastrointestinal TractOncology, 1985